Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Propensity score-matched analysis finds no significant PFS (HR 1.41; 95% CI 0.84–2.38) or OS (HR 1.01; 95% CI 0.54–1.90) difference between IgD and IgG/IgA pts getting ASCT; results unchanged after adjustment for race and SCr.”
Title: Post-Transplant Outcomes in IgD Multiple Myeloma: A Propensity Score-Matched Analysis
Authors: Curtis Marcoux, Denái R. Milton, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Arsalan Saeed, Asad A. Haider, Jeremy Ramdial, Sohaib Irfan, Yago Nieto, Guilin Tang, Yosra Aljawai, Partow Kebriaei, Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, and Oren Pasvolsky
You can read the Full Article in Transplantation and Cellular Therapy.
You can find more posts featuring Robert Orlowski on OncoDaily.
